Circulating Extracellular Vesicles: An Effective Biomarker for Cancer Progression. Front Biosci (Landmark Ed) 2024 Oct 31;29(11):375
Date
11/30/2024Pubmed ID
39614441DOI
10.31083/j.fbl2911375Scopus ID
2-s2.0-85209875740 (requires institutional sign-in at Scopus site) 3 CitationsAbstract
Extracellular vesicles (EVs), the ubiquitous part of human biology, represent a small heterogenous, membrane-enclosed body that contains a diverse payload including genetic materials in the form of DNA, RNAs, small non-coding RNAs, etc. mostly mirroring their source of origin. Since, a vast majority of research has been conducted on how nucleic acids, proteins, lipids, and metabolites, associated with EVs can be effectively utilized to identify disease progression and therapeutic responses in cancer patients, EVs are increasingly being touted as valuable and reliable identifiers of cancer biomarkers in liquid biopsies. However, the lack of comprehensive clinical validation and effective standardization protocols severely limits its applications beyond the laboratories. The present review focuses on understanding the role of circulating EVs in different cancers and how they could potentially be treated as cancer biomarkers, typically due to the presence of bioactive molecules such as small non-coding RNAs, RNAs, DNA, proteins, etc., and their utilization for fine-tuning therapies. Here, we provide a brief general biology of EVs including their classification and subsequently discuss the source of circulatory EVs, the role of their associated payload as biomarkers, and how different cancers affect the level of circulatory EVs population.
Author List
Chatterjee M, Gupta S, Nag S, Rehman I, Parashar D, Maitra A, Das KAuthor
Deepak Parashar PhD Assistant Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Biomarkers, TumorDisease Progression
Extracellular Vesicles
Humans
Liquid Biopsy
Neoplasms
